Securing sterile drug product capacity for early-phase development has never been more challenging. The revised EU GMP Annex 1 guidelines have raised expectations across contamination control, environmental monitoring, and aseptic process validation at precisely the moment global sterile capacity is under its greatest strain.

For early-stage biotech and emerging pharma, the impact is immediate. Timelines are extending, CMC packages are taking longer to complete, and the gap to Phase I is widening. This webinar cuts through the complexity. Upperton’s sterile development and operational experts will explain how the Annex 1 landscape is reshaping facility expectations, supply chain strategy, and early-phase development timelines.

You will also see how a structured, single-site approach can take a sterile programme from first formulation to a clinical submission-ready CMC package in as little as 16 weeks, subject to molecule readiness, scope, and prompt sponsor input.

This webinar will highlight practical strategies for navigating CDMO selection, Annex 1 with confidence, and how making informed early formulation decisions can achieve faster clinical submission readiness.